Conference Description:

With the EMA's guidance on the use of real world evidence in its regulatory decision-making, and federated learning networks that continue to support pharma, the integration of real world evidence into clinical research is transforming drug development.

Following on from the 11th IMPACCT Real World Evidence Summit US, created-by biopharma-for biopharma, the IMPACCT Real World Evidence Summit Europe stands out as the only European industry-led meeting dedicated to the practical applications of real world evidence across all stages of clinical research from patient identification through to phase IV that will empower you to revolutionise your clinical research capabilities.

Coming to Amsterdam in February 2024, the summit will gather biopharma for an unparalleled learning and networking opportunity, enabling you and your team to bridge the evidence gap between clinical research and practice in a time-efficient and cost-effective way.

Tickets: https://go.evvnt.com/2069223-2?pid=154
Time: 9:00 am - 4:00 pm

Prices:
Drug Developer- Conference Only: EUR 2799.00,
Drug Developer - Conference + 1 Workshop: EUR 3298.00,
Drug Developer - Conference + 2 Workshops: EUR 3797.00,
Solution Provider - Conference Only: EUR 3399.00,
Solution Provider Conference + 1 Workshop: EUR 3989.00,
Solution Provider + 2 Workshops: EUR 4597.00,
Academic - Conference Only: EUR 2399.00,
Academic - Conference + 1 Workshop: EUR 2798.00,
Academic - Conference + 2 Workshops: EUR 3197.00

Speakers: Abaigeal Jackson, Medical Affairs Scientist and Real World Evidence, Pfizer, Alex Liede, Senior Director, Abbvie, Emmi Tikkanen, Senior Medical Affairs Data Expert, Pfizer, Erwin Bruninx, Senior Medical Advisor RWE, Pfizer, Helene Chevrou-severac, Senior Director and Head of Real World Evidence and Outcomes Centre of Excellence, Alexion, Jesper Kjær, Director of Data Analytics Centre, Danish Medicines Agency, Joan Mendivil, Head Evidence and Outcomes Research, Pharvaris, Laura Fabbri, Head of Real World Evidence Department, Chiesi Farmaceutici, Lene Hammer-Helmich, Director and Head of Real World Evidence and Epidemiology, Lundbeck, Lill-Brith von Arx, RWE Northern Europe Hub Lead, Eli Lilly, Nadir Ammour, Global Lead, Clinical Innovation and External Partnership, Sanofi, Peter Rijnbeek Prof.dr.ir., Head of Department of Medical Informatics, Erasmus, Pierre-Alexandre Squara, RWE medical manager, Pfizer, Sebastian Kloss, Global Real World Evidence and Epidemiology Lead, Menarini, Stefania Pirondi, Head of Clinical project management Unit, Chiesi Farmaceutici, Steve Morris, Vice President, Director and Head of Medical Affairs, Alimera Sciences